β细胞在驱动肝硬化患者肝移植后糖尿病缓解中的核心作用
这项观察性纵向研究对80例血糖正常的肝硬化患者移植前后行扩展口服葡萄糖耐量试验,用数学模型评估β细胞功能、胰岛素清除与胰岛素敏感性。2年随访中63.9%的糖尿病患者缓解,β细胞功能改善驱动的胰岛素生物利用度增加在糖尿病缓解中起核心作用。
要点
- 80例肝硬化患者中基线糖尿病36例(45%),非糖尿病44例(55%)。
- 2年随访中23例糖尿病患者缓解(63.9%),4例非糖尿病者进展为糖尿病(9.1%)。
- β细胞功能改善驱动胰岛素生物利用度增加,在糖尿病缓解中起核心作用。
核心结论
- β细胞功能改善驱动的胰岛素生物利用度增加在持续改善的胰岛素敏感性背景下,对肝移植后糖尿病缓解起核心促进作用。
- β细胞功能是决定肝硬化肝移植患者糖代谢有利或不利变化的关键过程。
研究设计与样本
- 观察性纵向研究,纳入80例空腹血糖和HbA1c水平非糖尿病的肝硬化患者。
- 移植前及移植后3、6、12、24个月行扩展口服葡萄糖耐量试验(OGTT)。
- 用数学模型估算β细胞功能的导数控制(DC)和比例控制(PC)及胰岛素清除,用OGIS-2h指数估算胰岛素敏感性。
主要发现
- 基线时糖尿病患者36例(45%),非糖尿病44例(55%)。
- 2年随访中23例糖尿病患者缓解(63.9%),13例未缓解(36.1%);4例非糖尿病者进展为糖尿病(9.1%),40例未进展(90.9%)。
- 缓解者DC和PC均升高(分别自第3个月和第24个月起),进展者DC和PC均降低;未缓解者保持稳定,未进展者仅PC降低。
- 除进展者外,所有组胰岛素清除均增加;OGIS-2h在所有组第3个月均改善,此后仅缓解者继续改善,其他组回到基线值。
临床怎么用
- 作者指出,需要开发维持这些患者β细胞功能的治疗手段。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Diabetes occurring as a direct consequence of loss of liver function is usually characterized by non-diabetic fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) levels and should regress after orthotopic liver transplantation (OLT). This observational, longitudinal study investigated the relationship between the time-courses of changes in all 3 direct determinants of glucose regulation, i.e., β-cell function, insulin clearance and insulin sensitivity, and diabetes regression after OLT. METHODS: Eighty cirrhotic patients with non-diabetic FPG and HbA1c levels underwent an extended oral glucose tolerance test (OGTT) before and 3, 6, 12 and 24 months after OLT. The OGTT data were analysed with a mathematical model to estimate derivative control (DC) and proportional control (PC) of β-cell function and insulin clearance (which determine insulin bioavailability), and with the Oral Glucose Insulin Sensitivity (OGIS)-2 h index to estimate insulin sensitivity. RESULTS: At baseline, 36 patients were diabetic (45%) and 44 were non-diabetic (55%). Over the 2-year follow-up, 23 diabetic patients (63.9%) regressed to non-diabetic glucose regulation, whereas 13 did not (36.1%); moreover, 4 non-diabetic individuals progressed to diabetes (9.1%), whereas 40 did not (90.9%). Both DC and PC increased in regressors (from month 3 and 24, respectively) and decreased in progressors, whereas they remained stable in non-regressors and only PC decreased in non-progressors. Insulin clearance increased in all groups, apart from progressors. Likewise, OGIS-2 h improved at month 3 in all groups, but thereafter it continued to improve only in regressors, whereas it returned to baseline values in the other groups. CONCLUSIONS: Increased insulin bioavailability driven by improved β-cell function plays a central role in favouring diabetes regression after OLT, in the presence of a sustained improvement of insulin sensitivity. LAY SUMMARY: Diabetes occurring in cirrhosis as a direct consequence of loss of liver function should regress after transplantation of a new functioning liver, though the pathophysiological mechanisms are unclear. This is the first study evaluating the contribution of all 3 direct determinants of insulin-dependent glucose regulation using a sophisticated mathematical model. Results show that β-cell function is the key process governing favourable or detrimental changes in glucose regulation in cirrhotic patients undergoing transplantation, pointing to the need to develop therapies to sustain β-cell function in these individuals. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02038517.
引用
- Grancini V, Trombetta M, Lunati ME, et al. Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients. J Hepatol. 2019. PMID: 30677460. doi:10.1016/j.jhep.2019.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。